Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Chemomab Therapeutics ( (CMMB) ) has shared an update.
Chemomab Therapeutics Ltd. announced a change in the ratio of its American Depositary Shares (ADSs) to ordinary shares, effective August 26, 2025. This adjustment will result in one ADS representing eighty ordinary shares, effectively a one-for-four reverse ADS split. The Bank of New York Mellon will manage the exchange of existing ADSs, with no new ADSs issued. This move is expected to streamline the company’s ADS structure, potentially impacting its market positioning and shareholder value.
The most recent analyst rating on (CMMB) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Chemomab Therapeutics stock, see the CMMB Stock Forecast page.
Spark’s Take on CMMB Stock
According to Spark, TipRanks’ AI Analyst, CMMB is a Underperform.
Chemomab Therapeutics’ overall stock score is low due to significant financial challenges, including zero revenue and sustained losses. The technical analysis indicates mixed signals but does not currently show strong upward trends. The valuation metrics reflect high risk without profitability or income generation. The company’s future performance heavily relies on its ability to develop and commercialize products successfully.
To see Spark’s full report on CMMB stock, click here.
More about Chemomab Therapeutics
Chemomab Therapeutics Ltd. operates in the biotechnology industry, focusing on developing therapeutics for fibrotic and inflammatory diseases. The company is based in Tel-Aviv, Israel, and is listed on the Nasdaq Capital Market under the ticker ‘CMMB’.
Average Trading Volume: 154,368
Technical Sentiment Signal: Sell
Current Market Cap: $19.24M
Find detailed analytics on CMMB stock on TipRanks’ Stock Analysis page.